Congenital generalised lipodystrophy

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Amryt Pharmaceuticals Designated Activity Company Commercial
    METRELEPTIN
    2022-501781-22-00 4 countries 2024 n=25 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amryt Pharmaceuticals Designated Activity Company Commercial 1 Phase III 0
New trials by year
2024
1
← All indication landscapes